METASTATIC BREAST

METASTATIC PROSTATE

METASTATIC COLORECTAL

CELLSEARCH® Circulating Tumor Cell (CTC) Test

The CELLSEARCH® Circulating Tumor Cell (CTC) Test is the only FDA-cleared test that can capture and count CTC's for metastatic breast, prostate or colorectal cancer. CTC’s are an accurate predictor of progression free survival and overall survival, allowing for well-informed clinical decisions.

​

Health care providers can use the CELLSEARCH® Circulating Tumor Cell (CTC) Test to assess the success of a line of therapy much earlier and more frequently than what is typical with imaging (around 3 months and in some cases more). Changes in a patient’s prognosis can be readily identified when changes in the number of CTC’s are measured.

​

Earlier and more frequent information is invaluable to the physician, the patient and their families because:

​

• targeted therapies can be much more costly,

​

• detecting changes in a patient’s prognosis earlier may allow for a change in the treatment plan and

​

• cancer patients may be able to avoid unnecessary side effects of therapies that are either not effective or that have become ineffective over the course of the treatment.